PureTech Health plc
PRTCY
Other OTC15.85
USD
-0.15
- -
PureTech Health plc
PRTCY
(Other OTC)
Recent
price
15.85
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- PureTech Health plc is a clinical stage biotechnology company focused on the discovery, development, and commercialization of therapies for rare diseases and immuno-oncology indications led by a portfolio of in- and out-licensed asset programs. The company develops and advances therapies from its pipeline through to clinical trials and potential commercialization, leveraging its translational platform and collaborations with industry partners to expedite development timelines and optimize patient impact. Main products and services - Therapeutic product development: discovery, preclinical research, and clinical development of novel medicines across multiple programs, with a focus on orphan diseases and immuno-oncology; activities include target identification, lead optimization, pharmacology, toxicology, and phase-specific clinical trial execution - Pipeline assets by program, including finish-to-market development for lead compounds and supporting compounds in the same therapeutic areas; management of translational science, biomarker strategy, and regulatory submission readiness - Strategic partnerships and collaboration management: structuring and executing research collaborations, licensing agreements, and joint development arrangements with biotech and pharmaceutical partners to advance assets through clinical stages - Intellectual property development and protection: securing and maintaining patent estates around novel therapeutic mechanisms, manufacturing processes, formulation technologies, and companion diagnostics - Manufacturing and process development: chemistry, manufacturing, and control (CMC) strategies for clinical-grade material, scale-up planning, and technology transfer activities aligned with regulatory expectations - Corporate and investor relations services: disclosure management, ESG reporting support, financial communications, and engagement with shareholders and potential investors Latest major company changes - Strategic partnerships and alliances: enters and expands collaboration agreements with multiple pharmaceutical partners to advance portfolio programs and leverage shared development resources - Funding rounds and corporate activity: secures financing through equity and strategic funding rounds to support continued clinical development and pipeline expansion - New product and platform developments: advances new therapeutic candidates and platform technologies through early-stage clinical programs; expands translational research capabilities and biomarker-driven trial design - Business expansion and restructuring: reorganizes pipeline prioritization and capital allocation to focus resources on high-potential assets; expands geographic reach for clinical and research activities - Corporate branding and governance: maintains ongoing governance enhancements and potential organizational realignments to support rapid development pace and investor transparency - Operational updates: implements process improvements in research operations, data management, and external collaboration frameworks to support accelerated timelines in the last 1-2 years Additional context - Industry and segments: biotechnology; rare disease therapeutics; immuno-oncology; translational medicine; clinical-stage biotech - Target markets and customers: patients with rare diseases and cancer indications; pharmaceutical and biotech partners; academic and research collaborators - Geographic operations: headquarters in the United Kingdom with clinical and research activities and partner networks spanning Europe, North America, and other regions - Founding year and headquarters: founded in the 2000s; headquarters located in the United Kingdom - Subsidiaries and parent relationships: operates as an independent publicly listed company with subsidiary entities as part of its corporate structure to support R&D, regulatory, and operational activities - Regulatory and clinical focus: pursues clinical trials under regulatory oversight in multiple jurisdictions, with emphasis on obtaining regulatory milestones and potential approvals for lead programs Note: Information reflects PureTech Health plc. For precise program names, asset designations, and current ownership or partnership details, refer to the company’s latest public disclosures and regulatory filings.